EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study

Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, Korean Association for the Study of Intestinal Diseases

Intestinal Research · 31.01.2023 · 21 (1) · 137-147

DOI: 10.5217/ir.2021.00173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.01.2023. Verfasst von Kyunghwan Oh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: We investigated the real-world effectiveness and safety of ustekinumab (UST) as induction treatment for Koreans with Crohn’s disease (CD).Methods: CD patients who started UST were prospectively enrolled from 4 hospitals in Korea. All enrolled patients received intravenous UST infusion at week 0 and subcutaneous UST injection at week 8. Clinical outcomes were assessed using Crohn’s Disease Activity Index (CDAI) scores at weeks 8 and 20 among patients with active disease (CDAI ≥150) at baseline. Clinical remission was defined as a CDAI

Schlagwörter

Stichwörter der Autor:innen

Crohn diseaseKoreaUstekinumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Oh, K., Hong, H. S., Ham, N. S., Lee, J., Park, S. H., Yang, S. K., Yoon, H., Kim, Y. S., Choi, C. H., Ye, B. D., & Korean Association for the Study of Intestinal Diseases (2023). Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intestinal Research, 21(1), 137-147. https://doi.org/10.5217/ir.2021.00173

Vancouver

Oh K, Hong HS, Ham NS, Lee J, Park SH, Yang SK, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intestinal Research. 2023;21(1):137-147. doi:10.5217/ir.2021.00173

BibTeX
@article{Oh2023,
  author = {Oh, Kyunghwan and Hong, Hee Seung and Ham, Nam Seok and Lee, Jungbok and Park, Sang Hyoung and Yang, Suk-Kyun and Yoon, Hyuk and Kim, You Sun and Choi, Chang Hwan and Ye, Byong Duk and Korean Association for the Study of Intestinal Diseases, Korean Association for the Study of Intestinal Diseases},
  title = {Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study},
  journal = {Intestinal Research},
  year = {2023},
  volume = {21},
  number = {1},
  pages = {137--147},
  doi = {10.5217/ir.2021.00173}
}
Kostenlos starten →